This study is looking at how effective a new combination of drugs, bictegravir (BIC) and lenacapavir (LEN), is compared to the current treatment for people with HIV-1 who are already doing well on Biktarvy (B/F/TAF). BIC and LEN are medications that help control the amount of HIV-1 virus in the body. To join, you must have been on B/F/TAF for at least six months and have very low virus levels in your blood. If you have recently had certain infections or health conditions, you may not be eligible.

• The study lasts about 48 weeks.
• You may have to visit the clinic several times.
• There might be risks, such as side effects from the new drugs.

If you are pregnant, breastfeeding, or have used LEN before, you cannot join this study. It's important to discuss with your doctor whether participating is right for you.